Most Read Articles
3 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Oral tranexamic acid safe, effective for moderate-to-severe melasma

31 Jan 2018

Oral tranexamic acid (TA) may help improve moderate-to-severe melasma with negligible side effects, according to a recent study.

Of the 44 patients included, 39 completed the study. Reduction in the modified Melasma Area and Severity Index (mMASI) score at 3 months was greater in the TA group than in the control group (49 percent vs 18 percent). Patients with severe melasma benefitted more from treatment than those with moderate melasma.

Three months after treatment cessation, reduction in mMASI score remained higher in the TA cohort compared with the baseline visit vs that in the placebo arm (26 percent vs 19 percent). There were no adverse events in either group.

This single-centre study enrolled predominantly Hispanic women. Patients with moderate-to-severe melasma received 250-mg TA or placebo capsules twice daily for 3 months and sunscreen, followed by 3 months of treatment with sunscreen only. The mMaSI score was the primary outcome measure.

In another study, researchers concluded that topical TA was effective for melasma, adding that suppression of endothelin-1 could be one of the mechanisms of action of TA on melasma. [Clin Exp Dermatol 2016;41:480-485]

A recent systematic review and meta-analysis has shown that TA is effective and safe, either alone or as an adjuvant to routine treatment modalities for melasma. [Acta Derm Venereol 2017;97:776-781]

“Melasma is a common pigmentary disorder that is often difficult to treat,” according to the investigators of the current study. “TA has emerged as a promising treatment for melasma; however, few controlled studies exist.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Nintedanib does not appear to improve survival in heavily pretreated patients with metastatic colorectal cancer (CRC), according to data from the phase III LUME-Colon 1 trial.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.